Company intelligence / Profile preview

Lyra Therapeutics, Inc.

Watertown, Massachusetts, United Stateslyratherapeutics.com ↗

Ownership: Public · LYRA
Employees: ~30
Development stage: Phase 3

Overview

LYR-210 did not meet its primary endpoint in the ENLIGHTEN 1 Phase 3 trial as announced in May 2024. The company is awaiting results from the ENLIGHTEN 2 pivotal Phase 3 trial expected in Q2 2025. Post-hoc analyses in CRS patients with nasal polyps showed positive results in the ENLIGHTEN 1 Extension Study.

Therapeutic areas: PulmonologyImmunology
Modalities: Anti-inflammatory drug delivery systemsBioresorbable nasal implants
Industry: Biotech

Drug pipeline

2 assets

LYR-201

1 more asset in the full pipeline.

Request access →

Partnerships

LianBio Inflammatory Limited

Financials

Market cap: $355K
Total revenue: $7K
Enterprise value: $14.7M

Beyond the preview

Go deeper on Lyra Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lyra Therapeutics, Inc..

Explore the full profile